

PHASE I I SCHEDULE

Week I	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
4-Apr-22	PA1.1, PA1.2 (L) (SGD)	Clinical Postings			L u n c h	PA2.1, PA2.6(L)	PH1.3 (SGD)	
5-Apr-22	PH1.1 (L)					MI 1.1 (L),(SGD)	MI 1.2(DOAP)	
6-Apr-22	MI 1.4 (L)					PA2.2, PA2.3(L)	PA2.8(DOAP)	
7-Apr-22	IM4.1 IM4.2, IM4.4 (L)					PH1.2 (L)	CM 7.1, 7.5 (SGD)	MI 1.4(L)
8-Apr-22	PH1.4 (L)						FM 1.1 & FM 1.3 (L)	PH1.4 (L)
9-Apr-22	SU7.1(L)	PA2.4 (L)	PH1.4 (L)	AETCOM 2.1 (SGD)	PA 2.5 (SGD)	CM 7.5, 7.8 (SGD)	OG1.1 (L)	
Week II	11.30- 12.30	8.30-9.30	9.30-10.30	10.30-11.30		1.00-2.00	2.00-3.00	3.00-4.00
11-Apr-22	PA 2.5 (SGD)	Clinical Postings			L u n c h	P A3.1(L)	PH1.4-SGD	
12-Apr-22	PH1.5(L)					MI 1.4, MI 1.5 (SGD)	MI 1.5	
13-Apr-22	MI 1.1(L)					P A3.2(SGD)	PA2.8(DOAP)	
14-Apr-22	IM4.3 IM4.5 (L)					PH1.5(L)	CM 7.5,7.8 (SGD)	MI 1.1(SDL)
15-Apr-22	PH1.6(L)						FM 1.4 -1.7 (L)	PH 1.8(L)
16-Apr-22	AETCOM 2.1 (SGD)	PA1.3 (SDL)	PA 11.3 (SDL)	PA 2.7 (SDL)	AETCOM 2.1 (SGD)	Pandemic module 2.1	Pandemic module 2.1	

Week III	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L u n c h	1.00-2.00	2.00-3.00	3.00-4.00
18-Apr-22	PA4.1 (L)	Clinical Postings				PA4.1 (L)	PH1.4-SGD & PH1.5-SGD	
19-Apr-22	PH1.9(L)					MI 1.1 (L)	MI 1.1 & MI 1.2(DOAP)	
20-Apr-22	MI8.9(SGD)					PA 4.3(L)	PA4.1, PA4.2 (SGD)	
21-Apr-22	IM4.8 (L)					PH1.10(L)	CM 7.5,7.8 (SGD)	MI 1.1(SGD)
22-Apr-22	PH1.13(L)						FM 1.9 (SGD)	PH1.13(L)
23-Apr-22	SU5.1 (L)					PA 5.1 (L)	PH1.14(L)	AETCOM 2.1 (Skills Lab)
Week IV	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L u n c h	1.00-2.00	2.00-3.00	3.00-4.00
25-Apr-22	PA 6.1, PA 6.2 (SGD)	Clinical Postings				PA 6.3 (SGD)	PH1.5-SGD	
26-Apr-22	PH1.14(L)					MI 1.1 (SGD)	MI 1.2(DOAP)	
27-Apr-22	MI 1.1(L)					PA 6.4 (L)	PA 4.4 (DOAP)	
28-Apr-22	IM4.9 IM4.10 (L)					PH1.15(L)	CM 7.3 (L)	MI 3.1 (SGD)
29-Apr-22	PH1.16(L)						FM 2.1 -2.5 (L)	PH1.16(L)
30-Apr-22	SU1.1 (L)					PA 6.4 (SGD)	PH1.16(L)	AETCOM 2.1 (SGD)
Week V	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L u n c h	1.00-2.00	2.00-3.00	3.00-4.00
2-May-22	PA 6.5, PA 6.6 , PA 6.7(SGD)	Clinical Postings				PA.7.1 (L)	PH1.7 -SGD(P) & PH1.8-SGD(P)	
3-May-22	PH1.16(L)					MI 1.1(L)	MI 1.1 (DOAP) MI 8.9(SGD)	
4-May-22	MI 1.1 (L)					PA.7.1 (L)	PA 5.1 (SGD + DOAP)	

5-May-22	IM1.1, IM1.5				n	PH1.16(L)	CM 7.2 (L)	MI 1.6 (L) (SGD)
6-May-22	PH1.17(L)						FM 2.6 - 2.8 (L)	PH1.18(L)
7-May-22	SU 2.1. 2.2 (L)	PA.7.2(L)	PH1.18(L)	AETCOM 2.2 (L)		PA.7.2 (L)	CM 8.4 (L)	OG 3.1 (L)
Week VI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
9-May-22	PA.7.3 (L)	Clinical Postings			L u n c h	PA.7.3 (SGD)	PH1.8-SGD(P)	
10-May-22	PH1.19(L)					MI 1.1(L)	MI 8.10(DOAP) ,MI 1.1(SGD)	
11-May-22	MI 1.1 (L)					PA.7.4(SGD)	PA 6.4, PA 6.7(DOAP) PA.7.1 (DOAP)	
12-May-22	IM1.6, IM1.7 (LL)					PH1.19(L)	CM 7.6 (L)	MI 1.1(L)
13-May-22	PH1.19(L)						FM 2.10 (SGD) & FM 2.11 (L)	PH1.19(L)
14-May-22	Pandemic module 2.2	AETCOM 2.2 (L)	Pandemic module 2.1	Pandemic module 2.1		Pandemic module 2.2	Pandemic module 2.2	Pandemic module 2.2
Week VII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
		Integration week I- Immune responses and Autoimmunity (PA 9.1 to PA 9.5)				Integration week I- Immune responses and Autoimmunity		
16-May-22	Principles and mechanisms in immunity(L) PA 9.1.M1.10	Clinical Postings			L u n c h	Hypersensitivity disorders (L) PA 9.2	Hypersensitivity disorders (SGD) PA 9.2	
17-May-22	Immunosuppressants PH 1.50					Hypersensitivity disorders (L) PA 9.2	Immunostimulants PH 1.50	
18-May-22	Etiopathogenesis of autoimmune disorders and immunodeficiency states MI 1.10 (L)					PA 9.5 SLE (L)	Newer methods of ELISA,ELFA,CLIA, IFA MI 1.8, 8.15	

19-May-22	Rheumatologic Problems IM7.1, IM7.2, IM7.3, IM7.4 (L)				L u n c h	Immunosuppressants PH 1.50	CM 5.1 (L)	Transplant rejections(SGD) PA 9.3
20-May-22	Monoclonal antibodies PH 1.42 , PH 1.43							FM 2.14 (SGD & DOAP)
21-May-22	Rheumatologic Problems IM7.5, IM7.6 (L)	Autoimmunity(L) PA 9.4	Calcineurin inhibitors PH 1.50	SLE(SGD) PA 9.5		Other AI diseases(SGD) PA 9.7, PA 33.5	CM 5.3(L)	Transplantation SU 13.1, 13.2 , 13.3 (L)
Week VIII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
23-May-22	PA.7.4 (SGD)	Clinical Postings			L u n c h	PA.7.5 (SGD)		
24-May-22	PH1.19(L)					MI.1.1(L)	MI1.1 & MI 1.2(DOAP)	
25-May-22	MI 1.7 (L)					PA 8.1. PA 8.2 (SGD)	PA 8.3 (DOAP)	
26-May-22	IIM6.1, IM6.2, IM6.3 (L)					PH1.19(L)	CM 10.5,, 8.3 (L)	MI 1.8 (L)
27-May-22	PH1.19(L)						FM 2.17 (SGD & L)	PH1.19(L)
28-May-22	SU1.3 (L)					PA 9.6 (L)	PH1.24(L)	AETCOM 2.3 (Seminar)
Week IX	11.30- 12.30	8.30-9.30	9.30-10.30	10.30-11.30	L	1.00-2.00 (1-1.55)	2.00-3.00 (1.55-2.50)	3.00-4.00 (2.50-3.45)
30-May-22	PA.10.1,PA.10.2,PA.10.4 (SGD)	Clinical Postings			u n c h	PA 11.1 (SGD)	PH1.12 -SGD(P)	
31-May-22	PH1.24(L)					MI 1.8(L)	MI 1.2(DOAP)	
1-Jun-22	MI 1.8 (L)(SDL)					PA 11.2 (SGD)	PA 10.3 (SGD) PA 10.3 (DOAP)	
2-Jun-22	IIM6.4, IM6.5, IM6.7 (L)					PH1.25(L)	CM 5.3 (SGD)	MI 1.8(L)
3-Jun-22	PH1.25(L)						FM 2.20 (L)	PH1.26(L)

4-Jun-22	SU 4.1, SU4.2 (L)	PA 12.1, PA 12.2 (SGD)	PH1.27(L)	AETCOM 2.3 (Seminar)		PA 12.3(SGD)	CM 5.3 (SGD)	OG 4.1 (L)
Week X	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L	1.00-2.00	2.00-3.00	3.00-4.00
6-Jun-22	PA13.1,PA13.2 (SDL)	Clinical Postings			u	PA13.3 (SGD)	PH1.13- SGD	
7-Jun-22	PH1.27(L)					MI 1.8(L)	MI 1.8 &MI 8.5 (DOAP)	
8-Jun-22	MI 1.8(L)					PA13.4 (L)	PA13.3 (SGD)	PA13.3 (SGD)
9-Jun-22	IM9.1, IM9.2 (L)					PH1.28(L)	CM 5.3(L)	MI 1.10 (L)
10-Jun-22	PH1.29(L)						FM 2.21&2.22 (L)	PH1.31(L)
11-Jun-22	AETCOM 2.4 (Vist)					AETCOM 2.4 (Vist)	AETCOM 2.4 (Vist)	AETCOM 2.4 (Vist)
Week XI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L	1.00-2.00	2.00-3.00	3.00-4.00
13-Jun-22	PA14.2(L)	Clinical Postings			u	PA14.2 (SGD)	PH1.13 - SGD	
14-Jun-22	PH1.32(L)					MI 1.10	MI 1.2, MI 1.8, MI 8.15(DOAP)	
15-Jun-22	MI 1.10(L)					PA15.1, PA 15.4	PA13.5 (DOAP)	
16-Jun-22	IM1.3, IM1.9(L)					PH1.34(L)	CM 5.1 (SGD)	MI 1.11(L)
17-Jun-22	PH1.35(L)						FM 2.25 (L)	PH1.36(L)
18-Jun-22	SU12.1, 12.2 , 12.3 (L)					PA15.1 (L)	c PH1.36(L)	AETCOM 2.4 (SGD)
Week XII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L	1.00-2.00	2.00-3.00	3.00-4.00
20-Jun-22	PA16.1 , PA16.2 (L)	Clinical Postings			u	PA16.3 (L)	PH1.20 - SGD & PH1.21 - SGD	
21-Jun-22	PH1.37(L)					MI 1.9(L)	MI 1.2 MI 8.7(DOAP)	
22-Jun-22	MI8.5 8.6 & 7 (SGD)					PA16.3 (L)	PA14.3 (SGD)	PA14.3 (DOAP)
23-Jun-22	IM1.3(L)					PH1.38 (L)	CM 5.3 (SGD)	MI 1.1(L)
24-Jun-22	PH1.38 (L)						FM 2.25&2.26 (SGD)	PH1.39(L)
25-Jun-22	SU 15.1 (L)					PA16.4 (L)	PH1.40(L)	OG 23.1 (L)

Week XIII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
		II Integration week- Tuberculosis				II Integration week- Tuberculosis		
27-Jun-22	Common ethiological agents of respiratory tract infections MI.6.3	Clinical Postings			L u n c h	Describe the pathogenesis and pathology of tuberculous lymphadenitis PA 19.2	Describe the drugs used in MDR and XDR Tuberculosis PH 1.45	
28-Jun-22	Describe the first line antitubercular drugs, their mechanisms of action, side effects and doses. PH 1.44					Discuss the Laboratory Diagnosis of Tuberculosis MI 6.3	Identify the common etiologic agents of lower respiratory tract infections (Gram Stain & Acid fast stain) MI 6.3,	
29-Jun-22	Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of pulmonary tuberculosis PA 26.4					Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of pulmonary tuberculosis PA 26.4	Identify and describe the features of tuberculous lymphadenitis in a gross and microscopic specimen PA 19.3	
30-Jun-22	IM 3.1 (L)					Describe the drugs used in MDR and XDR Tuberculosis PH 1.45	CM 8.1 (L)	Non Tuberculosis mycobacterial disease MI6.3

1-Jul-22	Describe the drugs used in MDR and XDR Tuberculosis PH 1.45					FM 2.35 (SGD)	Describe vaccines and their uses PH 1.54	
2-Jul-22	IM 3.2, 3.3 (L)	Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine PA 24.5	Describe the drugs used in MDR and XDR Tuberculosis PH 1.45	AETCOM 2.4 (SGD)	L u n c h	Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine PA 24.5	CM 8.1 (L)	OG 5.2 (L)
Week XIV	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
4-Jul-22	PA 17.1 (L)	Clinical Postings			L u n c h	PA 17.1, PA 17.2 (SGD)	PH1.22 - SGD & PH1.23 - SGD	
5-Jul-22	PH1.41(L)					MI 8.5, 8.6 (SDL)	MI 8.7 (DOAP)	
6-Jul-22	MI6.1(L)					PA18.1 (SGD)	PA15.3 (SGD)	PA15.3 (DOAP)
7-Jul-22	IM1.3(L)					PH1.42(L)	FM 3.3 -3.5 (L)	MI 8.5, 8.6 (SGD)
8-Jul-22	PH1.43(L)						CM 5.6(L)	PH1.43(L)
9-Jul-22	Pandemic module 2.2					AETCOM 2.4 (SGD)	AETCOM 2.5 (L)	AETCOM 2.5 (SGD)
Week XV	11.30- 12.30	8.30-9.30	9.30-10.30	10.30-11.30		1.00-2.00 (1-1.55)	2.00-3.00 (1.55-2.50)	3.00-4.00 (2.50-3.45)
11-Jul-22	PA18.2 (L)	Clinical Postings			L u n c h	PA18.2 (L)	PH1.32 - SGD	
12-Jul-22	PH1.43(L)					MI 2.1, 2.2(L)	MI 2.4, 2.3, 8.15 (SGD)(DOAP)	
13-Jul-22	MI 8.1(SGD)					PA18.2 (L)	PA16.6(DOAP)	PA16.7(DOAP)

14-Jul-22	IM2.1, IM2.2, IM2.3, IM2.4 (L)				c h	PH1.44(L)	CM 5.8 (SGD)	micro			
15-Jul-22	PH1.45(L)						FM 3.6 -3.8 (L)	PH1.46(L)			
16-Jul-22	SU 16.1 (L)	PA18.2 (L)	PH1.47(L)	OG 23.2(L)		PA19.1 (L)	CM (L)	OG 6.1(L)			
Week XVI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00 (1-1.55)	2.00-3.00 (1.55-2.50)	3.00-4.00 (2.50-3.45)			
18-Jul-22	PA19.4 (L)	Clinical Postings			L u n c h	PA19.4 (L)	PH1.32 - SGD& PH1.33 -SGD				
19-Jul-22	PH1.47(L)					MI 3.3(L)	MI 3.4, 8.15 (DOAP)				
20-Jul-22	MI 1.1(SDL)					PA19.5 (L)	PA18.1 (DOAP)	PA18.2 (DOAP)			
21-Jul-22	IM2.5 (L)					PH1.48(L)	CM 8.2 (L)	MI 1.1 (L)			
22-Jul-22	PH1.48(L)						FM 3.9 &3.10 (L& SGD)	PH1.49(L)			
23-Jul-22	SU6.1 (L)					PA19.6 (SGD)	PH1.49(L)	OG 23.3 (L)	PA20.1(L)	CM 8.2 (L)	OG 7.1 (L)
Assessment Week											
25-Jul-22	Pathology					Skill Assessment in Batches					
26-Jul-22	Pharmacology										
27-Jul-22	Microbiology										
28-Jul-22	Forensic Medicine										
29-Jul-22	General Medicine								General Surgery		
30-Jul-22	Community Medicine								Obstetrics and Gynecoogy		
Week XVII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00			
1-Aug-22	PA20. 1 (SGD)	Clinical Postings			L u n c h	PA20. 1 (SGD)	PH1.33 -SGD				
2-Aug-22	PH1.49(L)					MI 2.7(L)	MI 1.1, 2.7, 8.15(SGD)(DOAP)				
3-Aug-22	MI2.7(L)					PA 21.1 (SGD)	PA19.5 (DOAP)	PA19.7 (DOAP)			
4-Aug-22	IM2.14, IM2.15, IM2.16 (L)					PH1.50(L)	CM 3.1 (L)	MI1.1 (L)			

5-Aug-22	PH1.51(L)			
6-Aug-22	SU 10.1 , 10.2 (L)	PA 21.2 (L)	AETCOM 2.5 (SGD)	AETCOM 2.5 (SGD)
Week XVIII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30
8-Aug-22	PA 21.2 (L)	Clinical Postings		
9-Aug-22	PH1.54(L)			
10-Aug-22	MI2.5 (L)			
11-Aug-22	IM9.3, IM9.4, IM9.5, IM9.6, IM9.7, IM9.8 (L)			
12-Aug-22	PH1.56(L)			
13-Aug-22	AETCOM 2.5 (SDL)			
Week XIX	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30
15-Aug-22	PA 21.5(SGD)	Clinical Postings		
16-Aug-22	PH1.57(L)			
17-Aug-22	MI 1.1 (SGD)			
18-Aug-22	IM4.6 , IM4.7 (L)			
19-Aug-22	PH1.59(L)			
20-Aug-22	SU3.1 (L)			
Week XX	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30

	FM 3.11(SGD ,Autopsy)	FM3.11 (SGD)	
PH1.52(L)	CM 3.1 (L)	Assessment/ Remedial/ Sports	
	1.00-2.00	2.00-3.00	3.00-4.00
PA 21.3 (SGD)	PH1.34 -SGD		
MI2.5 MI 1.1 (L)	MI 1.2 (DOAP),MI1.1 (SGD)		
PA 21.4 (L)	PA 21.1 to 21.5 (SGD)	PA 21.1 to 21.5 (SGD)	
PH1.55(L)	CM 3.1 (SGD)	MI 1.1(SGD)	
	FM3.11 (SGD)	FM 3.20	
Pandemic module 2.3	Pandemic module 2.3	Pandemic module 2.3	
	1.00-2.00	2.00-3.00	3.00-4.00
PA22.4, PA 22.7(L)	PH1.34 -SGD		
MI 2.5(L)	MI 2.6. 8.15 (DOAP)		
PA22.5 (SGD)	PA22.2 (SGD)	PA22.2 (DOAP)	
PH1.58(L)	CM 3.5 (SGD)	MI 3.1(L)	
	FM 8.1 & 8.2 (L)	FM 8.3 - 8.5 (L)	
PH1.62(L)	CM 3.6 (L)	Assessment/ Remedial/ Sports	
	1.00-2.00	2.00-3.00	3.00-4.00

22-Aug-22	PA24.1 (L)	Clinical Postings			L u n c h	PA24.2 ,24.3, (L)	PH1.34 -SGD	
23-Aug-22	pharmac PH1.63(L)					MI3.1(L)	ML3.2, 8.15(DOAP)	
24-Aug-22	MI3.6, 3.1(SGD)					PA 24.4 (L)	PA.24.1 (DOAP)	PA24.2 ,24.3, 24.4(DOAP)
25-Aug-22	OG 8.1 (L)					PH1.64(L)	CM 8.1 (SDL)	MI 3.1 (SGD)
26-Aug-22	PH1.64(L)						FM 8.6 -8.8 (L)	FM 8.9 & FM 8.10 (L)
27-Aug-22	SU 14.1, 14.2 , 14.3 (L)	PA24.6(L)	AETCOM 2. 6(SGD)	Pandemic module 2.3	PH3.1 skill station	Pandemic module 2.3	Assessment/ Remedial/ Sports	
Week XXI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
29-Aug-22	PA24.7(L)	Clinical Postings			L u n c h	PA25.1(SGD)	PH2.1 DOAP	
30-Aug-22	PH3.1 skill station					MI4.1, 4.2,4.3(L)	MI3.8, 8.15(DOAP), MI 1.1(SGD)	
31-Aug-22	MI4.3(L)					PA25.3(L)	PA24.5; 24.6;24.7 (DOAP)	PA24.1 to 24.7(SGD)
1-Sep-22	IM5.1, IM5.2 (L)					PH3.1 skill station	CM 8.1 (SDL)	MI4.1(L)
2-Sep-22	PH3.1 skill station						FM 9.1 (SGD & seminar)	FM 9.1 (SGD & seminar)
3-Sep-22	SU 9.1 , 9.2 (L)	PA25.4(L)	AETCOM 2. 7(SGD)	AETCOM 2. 7(L)	PH3.1 skill station	CM 8.1 (SDL)	Assessment/ Remedial/ Sports	
Week XXII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
5-Sep-22	PA25.2; 25.5(L)	Clinical Postings			L u n c	PA 26.1 (L)	PH2.2 DOAP	
6-Sep-22	PH3.1 skill station					MI4.3(L)	MI4.3(SDL),MI 4.1, 4.3, 8.15(DOAP)	
7-Sep-22	MI4.3(L)					PA 26.2, ,26.3 (L)	PA 25.1-25.7 (SGD)	PA 25.1-25.7 (DOAP)
8-Sep-22	IM5.3, IM5.4 (L)					PH3.1 skill station	CM 8.1 (SDL)	MI4.3(L)

20-Sep-22	Insulin (L, SGD)PE 33.4, IM 11.2, IM 11.3- OG 12.3-	Clinical Postings
21-Sep-22	Agents causing wound infections MI4.3	
22-Sep-22	Gross and microscopic changes in organs (SGD) PA28.7-	
23-Sep-22	Insulin Resistance (L, SGD) PE 33.4, IM 11.2, IM 11.3- OG 12.3-	

N C H L U N C H	Methods of specimen collection and laboratory diagnosis of common infections in Diabetes(L) MI 17.3	Perform and identify the causative agents of infections in Diabetes(DOAP) MI 1.2	
	Charts (SGD) PA-28.7	Perform urine tests- sugar and ketone bodies and urinary dipstick tests (SGD, DOAP) PA 32.4, IM 11.11, 11.13, PE 335, PE	
	PH 1.36 Insulin analogue (L)	Epidemiology, control measures, use of lab tests at primary care level for DM (L,SGD) CM 8.2	Laboratory diagnosis of wound infections MI.4.3
		FM 9.3 (SGD)	FM 9.3 (L)

24-Sep-22	Lab investigations of DM (SGD, DOAP) PE 33.5, IM 11.11, IM 11.13-	Glomerular manifestation of DM (L, SGD) PA28.7	Oral antidiabetic drugs (L) PH 1.36	Enumerate and evaluate the need for screening tests (SGD, DOAP) CM 7.6		Feed Back	Formative Assessment/ Reflective exercise	Formative Assessment/ Reflective exercise
Week XXV	11.30- 12.30	8.30-9.30	9.30-10.30	10.30-11.30	L u n c h	1.00-2.00 (1-1.55)	2.00-3.00 (1.55-2.50)	3.00-4.00 (2.50-3.45)
26-Sep-22	PA 27.5 (L)	Clinical Postings				PA 27.4(L)	PH2.4 DOAP	
27-Sep-22	PH3.4 skill station					MI5.2(L)	MI4.3(SGD), 5.2, 8.15(DOAP)	
28-Sep-22	MI(5.2) L					PA 27.6(L)	PA 27.1 (DOAP)	PA 27.8(DOAP)
29-Sep-22	IM 3.1, 3.2, IM3.3 (L)					PH3.4 skill station	CM	MI 5.2(SGD)
30-Sep-22	PH3.4 skill station						FM 9.4 (SGD)	FM 9.4 (SGD)
1-Oct-22	SU 11.5 (L)	PA 27.2(SGD)	AETCOM 2.7(SGD)	Pandemic module 2.4		PH3.4 skill station	CM	Assessment/ Remedial/ Sports
Week XXVI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	L u n c h	1.00-2.00	2.00-3.00	3.00-4.00
3-Oct-22	PA 27.3, 27.7(SGD)	Clinical Postings				PA 27.9(SGD)	PH3.1 skill station	
4-Oct-22	PH3.4 skill station					MI6.1(L)	MI 5.2 (DOAP)	
5-Oct-22	MI4.1 ,1.1 (L)					PA 27.1 to 27.9(SGD)	PA 28.2 (SGD)	PA 28.3; 28.4 (SGD)
6-Oct-22	IM8.1, IM8.2, IM8.3 (L)					PH3.4 skill station	CM	MI 6.1 (SDL)
7-Oct-22	PH3.5 skill station						FM 9.4 (SGD)	FM 9.4 (L)

8-Oct-22	Pandemic module 2.4	PA 28.1 (SDL)	AETCOM 2.7(SDL)	AETCOM 2.7(SDL)	Pandemic module 2.4	Pandemic module 2.4	Pandemic module 2.4
Week XXVII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	1.00-2.00	2.00-3.00	3.00-4.00
10-Oct-22	PA 28. 2, 28.3, 28.4(L)	Clinical Postings			PA 28.5,28.6 (L)	PH3.1 skill station	
11-Oct-22	PH3.5 skill station				MI6.1(L)	MI 6.2 (DOAP)	
12-Oct-22	MI 6.1(SGD)				PA 28.7 (SGD)	PA 28,12,13,15 (SGD)	PA 28.14(DOAP)
13-Oct-22	IM8.4, IM8.5, IM8.6 (L)				PH3.5 skill station	CM 8. 1 (SGD)	MI 6.1 (SGD)
14-Oct-22	PH3.5 skill station					FM 9.5 (SGD)	FM 9.5 (SGD)
15-Oct-22	SU , 8.3 8.1 (L)	PA28.8,28.9(SGD)	AETCOM 2.8(Visit)	AETCOM 2.8(Visit)	PH3.5 skill station	CM 8. 1 (SGD)	Assessment/ Remedial/ Sports
Week XXVIII	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30	1.00-2.00	2.00-3.00	3.00-4.00
		IV Integration Meningitis			IV Integration Meningitis		
17-Oct-22	Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis. PA 35.1	Clinical Postings			Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis. PA 35.1	Treatment of bacterial meningitis	
18-Oct-22	Rational antibiotic use				Etiopathogenesis, clinical course & lab diagnosis of meningitis MI5.2(L)	laboratory diagnosis of agents causing meningitis MI5.3, MI 8.15(DOAP)	

L
u
n
c
h

L
u

19-Oct-22	Identify the microbial agents causing meningitis MI5.3	Clinical Postings			n c h	Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis. PA 35.1	Identify the etiology of meningitis based on given CSF parameters PA 35.3	
20-Oct-22	OG 9.1					Treatment of Viral meningitis	CM 8.1 (L)	Agents of aseptic meningitis MI5.1(L)
21-Oct-22	Treatment of Fungal meningitis						FM 9.5 SGD	FM 9.5 (Autopsy + Lecture)
22-Oct-22	OG 9.5 (L)					Treatment of TB meningitis	Feed Back	Formative Assessment/ Reflective exercise
	FORMATIVE ASSESSMENT					FORMATIVE ASSESSMENT		
24-Oct-22	Pathology					Skill Assessment n Batches		
25-Oct-22	Pharmacology							
26-Oct-22	Microbiology							
27-Oct-22	Forensic Medicine							
28-Oct-22	General Medicine							
29-Oct-22	Community Medicine					General Surgery		
						Obstetrics and Gynecology		
Week XXIX	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
31-Oct-22	PA 28.10 (SGD)	Clinical Postings			L u	PA 28.11 (SGD)	pharmac PH3.2 skill lab patho/pharmac/micro	
1-Nov-22	pharmac PH3.5 skill station					MI 6.1 (L))	MI 6.3 (DOAP)	

2-Nov-22	MI 6.1 (SGD)	Clinical Postings			n c h	PA 28.14, 28.16(L)	patho/pharmac/micro	
3-Nov-22	OG 19.1 (L)					pharmac PH3.5 skill station	CM 8. 1 (SGD)	MI 6.1 (SGD)
4-Nov-22	pharmac PH3.5 skill station						FM 9.6 (SGD)	Assessment/ Remedial/ Sports
5-Nov-22	SU6.2 (L)	PA 28 1 to PA 28.16 (SGD)	AETCOM 2.8(LGD)	Pandemic module 2.4		pharmac PH3.5 skill station	Assessment/ Remedial/ Sports	Assessment/ Remedial/ Sports
Week XXX	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
7-Nov-22	PA 29.1 (L)	Clinical Postings			L u n c h	PA 29.2, 29.4 (L)	pharmac PH3.3 skill lab &PH3.4 skill station patho/pharmac/micro	
8-Nov-22	pharmacPH3.5 skill station					MI 7.3(L)	MI 6.3, 1.2(DOAP)	
9-Nov-22	MI 7.3 (SGD)					PA 29.3, 29.5(SGD)	PA 29.2, 29.3(DOAP)	PA 29.1 to 29.5 (SGD)
10-Nov-22	OG 19.4 (L)					pharmacPH3.7 skill station	CM 8. 1 (SGD)	MI7.2(L)
11-Nov-22	pharmac PH3.7 skill station						FM 9.6 (SGD)	Assessment/ Remedial/ Sports
12-Nov-22	Pandemic module 2.5	AETCOM 2.8(SDL)	AETCOM 2.8(SDL)	Pandemic module 2.5	Pandemic module 2.5	Pandemic module 2.5	Pandemic module 2.5	
Week XXXI	8.30-9.30	9.30-10.30	10.30-11.30	11.30- 12.30		1.00-2.00	2.00-3.00	3.00-4.00
14-Nov-22	PA 30.1 (L)	Clinical Postings			L u n	PA 30.2, 30.9 (L)	pharmac PH3.4 skill station patho/pharmac/micro	
15-Nov-22	pharmac PH3.7 skill station					MI 7.2(SGD)	MI7.3, 7.1, 7.2(DOAP)(SDL)	
16-Nov-22	MI 8.5, MI 6.6(L)					PA 30.3(L)	PA 30.7,PA 30.8(SGD)	PA 30.7,PA 30.8(DOAP)

24-Dec-22	SU 7.2 (L)	PA35..2, 36.1 (SGD)	AETCOM	AETCOM	PH5.7 SGD	Assessment/ Remedial/ Sports	Assessment/ Remedial/ Sports
	SUMMATIVE ASSESSMENT/ MODEL EXAMNATION					SUMMATIVE ASSESSMENT/ MODEL EXAMNATION	
26-Dec-22	Pathology Paper I						
27-Dec-22	Pathology Paper II						
29-Dec-22	Pharmacooogy Paper I						
30-Dec-22	Pharmacooogy Paper II						
2-Jan-23	Mcrobiology Paper I						
3-Jan-23	Mcrobiology Paper II						
4-Jan-23	Pathology/ Pharmacooogy/ Microbiology				Practicals and Viva		
5-Jan-23							
6-Jan-23							
9-Jan-23							
10-Jan-23							
11-Jan-23							



